Signadori Bio Appoints Dr. Selwyn Ho, MB BS As Chief Executive Officer

Dr. Ho is an experienced biotech and biopharma leader with nearly 30 years of expertise in drug development, commercialisation, and product launches, with a focus on ophthalmology, immunology, and immuno-oncology. He has worked extensively with cell therapies, monoclonal antibodies, and multi-specific antibody technologies.

Dr. Ho is a biotech and biopharma executive with nearly 30 years of experience in drug development, commercialization, and product launches, specializing in ophthalmology, immunology, and immuno-oncology. He has worked extensively with cell therapies, monoclonal antibodies, and multi-specific antibody technologies.

Most recently, Dr. Ho served as CEO of Medigene AG, a Germany-based immuno-oncology company developing T-cell receptor (TCR)-guided therapies for solid tumours, including cell therapies and TCR-based treatments. He led the company’s shift toward off-the-shelf therapies and advanced key programs through regulatory approvals.

Read Also - German based Maguar Acquires Major Stake In GRC Firm GlobalSuite Solutions

Before this, he was EVP and Chief Business Officer at Connect Biopharma, a US-based immunology biotech listed on NASDAQ, where he helped secure major financing, supported a successful IPO, and expanded the company’s US operations.

“Signadori Bio’s vision to develop a next generation, in vivo engineered monocyte therapy for solid tumours, based on P21 expression, aims to address many of the challenges and unmet needs currently seen with immunotherapies and autologous cell therapies,” said, Dr. Selwyn Ho, Chief Executive Officer, Signadori Bio.

About Signadori Bio

Signadori Bio is a Paris-based preclinical biopharmaceutical company developing a next-generation, off-the-shelf monocyte immunotherapy platform to treat solid tumours. Founded by Dr. Jean-Luc Perfettini and Prof. Nathalie Chaput, and based on research from Gustave Roussy, the company focuses on using gene-modified monocytes to overcome the tumour microenvironment. Signadori Bio is backed by Sofinnova Partners.